Darzalex global sales reach $4.2 billion in Q2 2026

Genmab A/S (Nasdaq: GMAB) reported that worldwide net trade sales of DARZALEX (daratumumab) totaled $4,207 million in the second quarter of 2026, according to figures reported by Johnson & Johnson.

U.S. net trade sales reached $2,435 million, while sales in the rest of the world totaled $1,772 million. The figures include sales of the subcutaneous formulation, daratumumab and hyaluronidase-fihj, marketed in the U.S. under the tradename DARZALEX FASPRO.

Genmab receives royalties on worldwide net sales of DARZALEX, covering both intravenous and subcutaneous products, under an exclusive worldwide license granted to Johnson & Johnson's legal entity Janssen Biotech, Inc. to develop, manufacture, and commercialize daratumumab.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Hyperscale Data plans special Class B stock dividend for shareholders
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks